STOCK TITAN

Medtronic - MDT STOCK NEWS

Welcome to our dedicated page for Medtronic news (Ticker: MDT), a resource for investors and traders seeking the latest updates and insights on Medtronic stock.

Overview

Medtronic (MDT) is a global healthcare technology company renowned for its development and manufacture of innovative therapeutic medical devices. Operating across a broad spectrum of chronic and acute medical conditions, Medtronic delivers solutions that range from cardiac care to neuromodulation, spinal treatments, and diabetes management. Leveraging advanced technology in areas such as robotics, imaging, and artificial intelligence, the company is central in addressing some of the most challenging health problems of our time.

Core Business and Products

Medtronic’s operations are built on decades of experience in designing, manufacturing, and marketing a diverse portfolio of medical devices. Their offering includes therapeutic devices such as pacemakers, defibrillators, heart valves, and stents, as well as advanced surgical tools, spinal fixation devices, neurovascular products, and insulin pumps. Each product category is developed through a rigorous process that emphasizes quality, patient safety, and robust clinical evidence. The company’s products are engineered to meet the demanding needs of healthcare institutions and professionals in both domestic and international markets.

Technological Innovation

At the core of Medtronic’s success is its commitment to technological innovation. The company integrates advanced systems in medical robotics, data analytics, and state-of-the-art imaging to enhance procedural accuracy. For instance, its ecosystem that connects navigation, robotics, and data analytics exemplifies how integrated solutions can lead to more predictable outcomes in complex procedures. Medtronic has also embraced adaptive technology in neuromodulation, shown by its work in adaptive deep brain stimulation, which personalizes therapy based on real-time neural signals.

Global Market Position and Operational Excellence

Medtronic operates with a global mindset, reaching patients in more than 150 countries. With its operational headquarters in the United States and legal headquarters in Ireland, the company effectively navigates diverse regulatory landscapes to maintain compliance while delivering high-quality medical devices. Approximately half of its revenue comes from international markets, underscoring its significance as a major player in the global medtech industry.

Partnerships and Industry Collaborations

Strategic partnerships further strengthen Medtronic’s market position. Collaborations with leading companies, such as those in imaging technology, enhance its product capabilities and help integrate novel hardware, software, and data-driven insights into clinical practice. These collaborations not only improve procedural outcomes but also provide a competitive edge in a field that continuously demands innovative therapeutic solutions.

Commitment to Quality and Clinical Expertise

Medtronic’s approach is deeply rooted in a commitment to clinical excellence and rigorous research. Every device is developed in accordance with strict quality controls and regulatory standards to ensure patient safety and efficacy. This clinical rigor, combined with an insatiable curiosity and diverse expertise, defines the company’s continued success. It is this commitment that has enabled Medtronic to remain at the forefront of treating over 70 critical health conditions through a continuously evolving product pipeline.

Industry Impact and Relevance

For investors and healthcare professionals, Medtronic represents more than just a manufacturer of medical devices. It embodies the transformative power of innovation in medicine by consistently addressing unmet clinical needs and improving patient outcomes. The company’s comprehensive portfolio and its integration of breakthrough technologies have set a benchmark for safety, reliability, and clinical performance in the competitive medical technology landscape.

Summary

In summary, Medtronic’s strength lies in its global scale, technological prowess, and ability to integrate complex therapeutic solutions seamlessly into clinical workflows. Its dedication to alleviating pain, restoring health, and extending life makes it a foundational pillar in modern healthcare, continuously evolving to meet the dynamic needs of patients and physicians alike.

Rhea-AI Summary

Medtronic (NYSE: MDT) announced its participation in the Jefferies 2020 Global Healthcare Conference on June 3, 2020. Karen Parkhill, the CFO, will address questions at 2:30 p.m. EDT. A live audio webcast will be accessible via the Investor Events link on the Medtronic investor relations page, with a replay available later the same day. Medtronic operates globally, employing over 90,000 people and serving patients in more than 150 countries, focusing on advancing healthcare solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
conferences
-
Rhea-AI Summary

Medtronic (NYSE: MDT) announced its participation in the Bernstein 36th Annual Strategic Decisions Conference on May 29, 2020. CEO Geoff Martha will present and address questions starting at 9:00 a.m. EDT. The event will be held virtually and can be accessed through the Investor Events link on Medtronic's investor relations page. An archive of the presentation will be available later that day. Medtronic is a leader in medical technology, operating in over 150 countries and focused on improving global healthcare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
conferences
-
Rhea-AI Summary

Medtronic (NYSE: MDT) announced FDA approval for the Android version of its Guardian Connect continuous glucose monitoring (CGM) system. This system alerts users of potential high or low glucose events up to 60 minutes in advance and aims to enhance the diabetes management experience. The Guardian Connect app will introduce features such as an in-app Startup Wizard and customizable alert functions. A real-world study showed that predictive alerts helped patients avoid 65% of low glucose excursions. Updated systems are expected to ship in summer 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
none
Rhea-AI Summary

Medtronic plc (NYSE: MDT) reported Q4 2020 revenue of $6.0 billion, down 26% reported and 25% organic, impacted by COVID-19. Q4 GAAP diluted EPS was $0.48, while non-GAAP diluted EPS stood at $0.58, reflecting a 62% decline. FY20 revenue totaled $28.913 billion, a decrease of 5.4%. Despite these challenges, Medtronic announced a quarterly dividend increase to $0.58 per share, marking its 43rd consecutive year of dividend growth. The company also reported robust cash flow from operations of $7.2 billion and free cash flow of $6.0 billion, showcasing its strong financial position.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
dividends earnings
-
Rhea-AI Summary

Medtronic announces the U.S. launch of Kyphon Assist™ Directional Cannula, designed for use with balloon kyphoplasty (BKP) products to treat vertebral compression fractures. This innovative device enhances physician control during procedures and improves height restoration. The Kyphon Assist is compatible across Medtronic's BKP product portfolio, offering benefits like directional control and reduced cement leakage. Vertebral compression fractures affect 1.4 million people globally, with many at risk due to osteoporosis. Medtronic aims to expand capabilities in vertebral augmentation treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
none
-
Rhea-AI Summary

Medtronic (NYSE: MDT) announced the appointment of Jeffrey J. Popma, M.D., as Vice President and Chief Medical Officer, effective June 22, 2020. Dr. Popma will lead medical initiatives in the Coronary, Renal Denervation, and Structural Heart divisions. With over 20 years in interventional cardiology, he aims to enhance cardiovascular device innovation and clinical research. His extensive experience includes directing numerous clinical trials and publishing over 500 scientific articles. Nina Goodheart and Geoff Martha expressed enthusiasm about Dr. Popma joining the executive team.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.34%
Tags
none
Rhea-AI Summary

Medtronic (NYSE: MDT) presented significant clinical trial results at the 2020 SCAI Scientific Sessions. The 10-year outcomes for the Melody™ Transcatheter Pulmonary Valve (TPV) showed robust long-term safety and effectiveness, with 97% of patients experiencing minimal pulmonary regurgitation. Additionally, the investigational Harmony™ TPV trial successfully met its primary endpoints at six months, with 89% of participants achieving acceptable hemodynamic function. These results underscore Medtronic's commitment to improving therapies for congenital heart disease patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
-
Rhea-AI Summary

Medtronic (NYSE:MDT) announced the FDA approval of its Cobalt and Crome implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy-defibrillators (CRT-Ds) featuring advanced remote monitoring via the MyCareLink Heart™ mobile app. Clinical trials presented during the virtual Heart Rhythm Society Scientific Sessions showed that patients using this app had a 94.6% adherence rate in monitoring, outperforming traditional methods. The Micra pacemaker showed a 66% reduction in complications, indicating its effectiveness in real-world settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.09%
Tags
none
-
Rhea-AI Summary

Medtronic plc (NYSE: MDT) will report its financial results for Q4 and full fiscal year 2020 on May 21, 2020, at approximately 5:45 a.m. CDT. A webcast discussion is scheduled for 7:00 a.m. CDT the same day. Financial results will cover the period ending April 24, 2020. Medtronic also plans to report its fiscal year 2021 results on August 25, November 24, February 23, and May 27 of 2021. The company's Institutional Investor & Analyst Day has been postponed due to the COVID-19 pandemic. More details will be announced closer to the specific event dates.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.25%
Tags
Rhea-AI Summary

Medtronic has expanded its Medtronic Assurance program to support U.S. diabetes customers who have lost their health insurance due to COVID-19-related job loss. Eligible customers can receive a 3-month supply of glucose sensors and insulin pump supplies at no cost. This initiative includes flexible payment plans and financial assistance for those significantly impacted by healthcare costs. The company aims to ensure continued access to diabetes technology during these challenging times.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.16%
Tags
covid-19

FAQ

What is the current stock price of Medtronic (MDT)?

The current stock price of Medtronic (MDT) is $88.49 as of April 1, 2025.

What is the market cap of Medtronic (MDT)?

The market cap of Medtronic (MDT) is approximately 113.8B.

What is the core business of Medtronic?

Medtronic develops and manufactures therapeutic medical devices for chronic diseases, including cardiac devices, neuromodulation, spinal therapies, and diabetes management tools.

How does Medtronic generate revenue?

The company generates revenue through the direct sale of its innovative medical devices and systems to healthcare institutions and professionals across the globe.

What markets does Medtronic serve?

Medtronic serves a global market, with significant operations in the United States, Europe, and other international markets, reaching patients in over 150 countries.

How does Medtronic maintain its competitive edge?

Medtronic maintains its competitive advantage through continuous technological innovation, strategic partnerships, and a commitment to clinical excellence and regulatory compliance.

What role do partnerships play in Medtronic's strategy?

Strategic partnerships, such as those with leading imaging and technology companies, enable Medtronic to integrate advanced features into its devices, thereby enhancing clinical outcomes and broadening its market reach.

How is Medtronic positioned in the medical technology industry?

Medtronic is a key player in the medtech industry, known for its comprehensive product portfolio, innovative technological solutions, and strong global market presence, addressing over 70 health conditions.

What types of products does Medtronic offer?

Medtronic offers a wide range of products including cardiac devices, spinal fixation systems, neurovascular products, insulin pumps, surgical tools, and advanced neuromodulation devices.

What distinguishes Medtronic's approach to innovation?

The company emphasizes rigorous clinical research, quality assurance, and the integration of cutting-edge technologies such as robotics and adaptive deep brain stimulation to deliver patient-centric solutions.

How does Medtronic address patient safety?

Medtronic adheres to strict quality controls and regulatory standards to ensure its devices are safe and effective, placing a high priority on patient outcomes and clinical performance.

What is Medtronic's global impact on healthcare?

By delivering innovative medical solutions and continuously evolving its product pipeline, Medtronic plays a critical role in transforming healthcare globally, positively impacting millions of patients every day.
Medtronic

NYSE:MDT

MDT Rankings

MDT Stock Data

113.81B
1.28B
0.26%
86.22%
1.05%
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
Ireland
GALWAY